[Sevelamer:hydrochloride]

Toru Hyodo1, Takayasu Taira, Haruki Wakai

  • 1Kidney Center, Yokohama Daiichi Hospital, Department of Urology, Kitasato University School of Medicine, Japan.

Clinical Calcium
|January 6, 2005
PubMed

Insights

Sevelamer hydrochloride inhibits coronary artery calcification progression in renal osteodystrophy patients. Strategies to manage constipation improved patient adherence, crucial for preventing calcification and improving survival.

Area of Science:

  • Nephrology
  • Cardiology
  • Pharmacology

Background:

  • Renal osteodystrophy is linked to coronary artery calcification (CAC) progression.
  • CAC is a significant risk factor for mortality in non-hemodialysis patients.
  • Sevelamer hydrochloride demonstrates inhibitory effects on CAC progression.

Purpose of the Study:

  • To investigate strategies for improving sevelamer hydrochloride adherence in Japanese patients.
  • To overcome the challenge of constipation, a common side effect limiting sevelamer hydrochloride use.
  • To enhance CAC prevention and long-term survival in patients with renal osteodystrophy.

Main Methods:

  • Patient education on the low incidence of CAC with sevelamer hydrochloride.
  • Co-administration of sorbitol, an osmotic purgative, to mitigate constipation.
  • Gradual replacement of calcium carbonate with sevelamer hydrochloride, starting with evening doses.

Main Results:

  • The implemented protocol significantly increased sevelamer hydrochloride intake.
  • An 86.7% patient adherence rate was achieved with the modified administration strategy.
  • This approach facilitates better management of CAC in renal osteodystrophy.

Conclusions:

  • Improving sevelamer hydrochloride intake is vital for preventing coronary artery calcification.
  • Effective management of side effects like constipation can enhance patient adherence.
  • Increased adherence to sevelamer hydrochloride contributes to improved long-term survival.

Related Concept Videos

Renal Failure: Dose Adjustments01:11

Renal Failure: Dose Adjustments

In patients with renal impairment, drugs undergo significant changes in their pharmacokinetics, which require dosage adjustments to ensure safe and effective therapy.
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
Antihypertensive Drugs: Thiazide-Class Diuretics01:15

Antihypertensive Drugs: Thiazide-Class Diuretics

Thiazide diuretics are sulfonamide derivatives featuring a benzothiadiazine ring system in their molecular structure. Based on this structure, thiazide diuretics can be categorized into two groups: thiazide-type and thiazide-like diuretics. Thiazide-type diuretics, including hydrochlorothiazide and chlorothiazide, consist of a benzothiadiazine backbone with an attached sulfonamide group. Thiazide-like diuretics, such as chlorthalidone and indapamide, lack the thiazide ring but demonstrate...
Antihypertensive Drugs: Direct Renin Inhibitors01:25

Antihypertensive Drugs: Direct Renin Inhibitors

The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
Drugs for Peptic Ulcer Disease: Sucralfate as Mucosal Protective Agents01:24

Drugs for Peptic Ulcer Disease: Sucralfate as Mucosal Protective Agents

In the intricate landscape of the gastric lumen, excessive acid secretion disrupts the natural defense mechanisms, weakening the mucus-bicarbonate barrier. This vulnerability allows pepsin to infiltrate epithelial cells, digesting mucosal proteins and triggering erosion, leading to ulcer formation.
In this scenario, mucosal protective agents like sucralfate play an essential role. Sucralfate, a complex of sulfated sucrose and aluminum hydroxide, demonstrates its usefulness in acidic conditions,...
Antihypertensive Drugs: Potassium-Sparing Diuretics01:28

Antihypertensive Drugs: Potassium-Sparing Diuretics

Liddle syndrome is a genetically inherited form of hypertension characterized by the overactivity of epithelial sodium channels in the nephron, the functional unit of the kidney. This heightened activity leads to increased sodium reabsorption and excessive excretion of potassium. To counteract this, potassium-sparing diuretics such as amiloride are used. They function by blocking these sodium channels, thereby reducing the influx of sodium into the epithelial cells and minimizing the loss of...
Renal Drug Excretion: Tubular Secretion01:28

Renal Drug Excretion: Tubular Secretion

Active tubular secretion is a robust, energy-demanding process that utilizes carrier systems to transport drugs into renal tubules. The active renal secretion systems include the organic anion transporter (OAT) for weak acids and the organic cation transporter (OCT) for weak bases. Structurally similar drugs can compete for the same transporter, potentially leading to drug accumulation and toxicity. However, this principle can be exploited therapeutically. One example is probenecid (Probalan),...